Clinical trial NCT00112554 - References

Leukemia — Cytarabine With or Without VNP40101M in Treating Patients With Relapsed Acute Myeloid Leukemia

Citation(s)

•   Giles F, Vey N, DeAngelo D, Seiter K, Stock W, Stuart R, Boskovic D, Pigneux A, Tallman M, Brandwein J, Kell J, Robak T, Staib P, Thomas X, Cahill A, Albitar M, O'Brien S
  Phase 3 randomized, placebo-controlled, double-blind study of high-dose continuous
•   Giles FJ, Stock W, Vey N, et al
  : A double blind placebo-controlled randomized phase III study of high dose continuous infusion cytosine arabinoside (araC) with or without cloretazine in patients with first relapse of acute myeloid leukemia (AML). [Abstra

A Phase III Randomized of Cloretazine™ (VNP40101M) and Cytosine Arabinoside (AraC) in Patients With Acute Myeloid Leukemia in First Relapse

Details for clinical trial NCT00112554